The Trichomoniasis market was valued at USD 411.37 Million in 2024 driven by increasing awareness and growing innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.70% during the forecast period of 2025-2034 and attain a market value of USD 651.18 Million by 2034.
Base Year
Historical Year
Forecast Year
The market is expected to grow steadily due to increased awareness, improved diagnostics, and expanding access to effective antimicrobial therapies.
Rising incidences of sexually transmitted infections, alongside enhanced screening programs, will drive demand for trichomoniasis diagnostics, leading to growth in testing kits and laboratory services.
The ongoing focus on preventive healthcare and education, particularly in high-risk populations, is anticipated to foster market expansion by reducing infection rates and increasing treatment adherence.
Trichomoniasis is a common sexually transmitted infection (STI) caused by the parasite Trichomonas vaginalis. It affects both men and women, though symptoms are more prominent in women, including vaginal discharge, itching, and discomfort. Men may experience urethral discharge or irritation. Early detection and treatment with antibiotics are crucial to prevent complications and transmission.
Global Health Strategies Set to Drive Trichomoniasis Market Expansion
Rising global awareness of sexually transmitted infections (STIs) and enhanced government healthcare initiatives are key drivers of growth in the market. According to the World Health Organization’s November 2024 fact sheet, approximately 156 million new cases of Trichomonas vaginalis infection occurred in 2020 among individuals aged 15–49. The WHO’s 2022–2030 Global Health Sector Strategy aims to reduce new cases of trichomoniasis by 50% by 2030. This ambitious target underscores the growing need for effective diagnostics, treatments, and preventive measures, thus fostering market expansion during the forecast period. Increased government investments and policy shifts will likely boost innovation in both therapeutic and diagnostic solutions, further driving market growth.
New Treatment Approvals to Boost Trichomoniasis Market Value
The growing focus on improving treatment options and approval of innovative therapies are key market drivers for the trichomoniasis sector. For instance, in February 2022, Lupin Pharmaceuticals announced the U.S. FDA’s approval of a supplemental New Drug Application (sNDA) for SOLOSEC (secnidazole), expanding its indication to include both bacterial vaginosis (BV) and trichomoniasis in patients aged 12 and older. SOLOSEC becomes the first and only single-dose oral antimicrobial agent approved for treating both conditions. This approval positions the product as a significant player in the trichomoniasis treatment market. The simplified, single-dose regimen is likely to improve patient compliance, potentially increasing the uptake of trichomoniasis treatments, and further driving market expansion.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Dosage Form
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Dosage Form to Witness Significant Growth
The oral dosage form is predicted to lead the market due to its convenience, ease of administration, and high patient compliance. Oral medications, such as metronidazole and tinidazole, are preferred as they can be easily taken at home, eliminating the need for medical supervision. This segment's dominance is driven by widespread availability, cost-effectiveness, and patient preference for non-invasive treatment options. Oral formulations also enable mass distribution in both developed and emerging markets, further expanding their market share.
The United States leads due to its advanced healthcare infrastructure, high awareness of sexually transmitted infections (STIs), and strong pharmaceutical sector. The presence of major global pharmaceutical companies, extensive research and development, and widespread healthcare access drive market dominance. Additionally, significant investments in STI diagnostics and treatments, coupled with robust public health campaigns, contribute to the U.S. market’s leadership, making it the largest and most developed segment in the global trichomoniasis market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in New York, USA, Pfizer was established in 1849 and is a global leader in the pharmaceutical industry. The company’s portfolio includes a wide range of treatments for infectious diseases, including trichomoniasis. Pfizer offers effective antimicrobial therapies, with a focus on developing novel treatments to combat STIs and improve patient outcomes.
Lupin, based in Mumbai, India, was founded in 1968. A prominent player in the global pharmaceutical market, Lupin’s portfolio includes generics, specialty medications, and active pharmaceutical ingredients (APIs). The company produces a range of antibiotics and treatments for infectious diseases, including trichomoniasis, leveraging its expertise in affordable, high-quality medications for global markets.
Zydus Group, headquartered in Ahmedabad, India, was established in 1952 and is a leading global pharmaceutical company. Its portfolio includes a variety of therapeutic segments, including antibiotics and treatments for infectious diseases. Zydus Group offers affordable generics for trichomoniasis, with a focus on improving access to essential medications across emerging markets.
F. Hoffman La Roche, founded in 1896 and headquartered in Basel, Switzerland, is a global leader in pharmaceuticals and diagnostics. Known for its innovative treatments, Roche’s portfolio spans oncology, infectious diseases, and diagnostics. The company’s contributions to the trichomoniasis market focus on research and developing diagnostic tools, alongside its range of antiviral therapies for STIs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Kesin Pharma and Sanofi.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Dosage Form |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share